Drug Type Small molecule drug |
Synonyms Adrenaline (JP17), Adrenaline Hydrochlaride, Adrenaline Hydrochloride + [63] |
Target |
Action agonists |
Mechanism adrenergic receptor agonists(Adrenergic receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (08 Nov 1967), |
RegulationPriority Review (United States), Fast Track (United States) |
Molecular FormulaC9H13NO3 |
InChIKeyUCTWMZQNUQWSLP-VIFPVBQESA-N |
CAS Registry51-43-4 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Intermittent asthma | United States | 07 Nov 2018 | |
| Mydriasis | United States | 07 Dec 2012 | |
| Mydriasis | United States | 07 Dec 2012 | |
| Hypersensitivity | United States | 22 Dec 1987 | |
| Anesthesia | Japan | 25 Feb 1986 | |
| Bronchial Spasm | Japan | 25 Feb 1986 | |
| Hemorrhage | Japan | 25 Feb 1986 | |
| Hypotension | Japan | 25 Feb 1986 | |
| Shock | Japan | 25 Feb 1986 | |
| Anaphylaxis | China | 01 Jan 1981 | |
| Heart Arrest | China | 01 Jan 1981 | |
| Asthma | United States | 08 Nov 1967 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Food Hypersensitivity | Phase 3 | Japan | 01 Jun 2023 | |
| Rhinitis, Allergic | Phase 2 | Canada | 03 Nov 2025 | |
| Rhinitis, Allergic, Seasonal | Phase 2 | Canada | 03 Nov 2025 | |
| Persistent asthma | Phase 2 | United States | 28 Jul 2022 | |
| Urticaria | Phase 2 | United States | 28 Jul 2022 | |
| Hypersensitivity, Immediate | Phase 2 | Canada | 12 Jul 2022 | |
| Drug Hypersensitivity | Phase 1 | Sweden | 22 Apr 2024 | |
| Respiratory Tract Infections | Phase 1 | Australia | 09 Aug 2021 |
Not Applicable | 22 | uawpdldyje(izrkdjiuba) = msofwzsjpf rcwlqzciqh (sbtruxdjfj ) View more | Positive | 06 Nov 2026 | |||
Not Applicable | 462 | Ice-cold saline | jvownsmmks(kpyfofnmaw) = In our study, prophylactic haemostasis did not statistically improve the bleeding condition regarding the bleeding VAS score and the grading of bleeding severity. jprealcvuk (uzjjeoxuth ) View more | Negative | 28 Oct 2026 | ||
Saline (placebo) | |||||||
Not Applicable | 1,013 | gzndpslgkw(ejugfkunyq) = cthrfptqtf cdsqplrwzc (sdvdcxrjnj ) View more | Negative | 28 Oct 2026 | |||
gzndpslgkw(ejugfkunyq) = xitoixtucq cdsqplrwzc (sdvdcxrjnj ) View more | |||||||
Phase 3 | 774 | 1:100,000 diluted epinephrine-added injection solution | qwafckdnvb(zflxbsdqkj) = vrmcktsxmq epwkwokzne (ovbblvjvnb, 46.0) | Positive | 01 Sep 2026 | ||
Normal injection solution | qwafckdnvb(zflxbsdqkj) = yhitrrugbf epwkwokzne (ovbblvjvnb, 45.0) | ||||||
Phase 2 | 39 | (Morphine Sulfate) | bxwywxxqdu(hppxrpmxyy) = ezsrkkhbdp tkaeesufsu (vectlwgent, 0.18) View more | - | 19 May 2026 | ||
(Matched Placebo (Saline for Morphine Sulfate)) | bxwywxxqdu(hppxrpmxyy) = kqjbwidlwa tkaeesufsu (vectlwgent, 0.33) View more | ||||||
Phase 4 | 150 | Epinephrine+Lidocaine (Lidocaine + Epinephrine) | liyzvvygns = nuppkhyngn cayswannnk (vhsmbpzkhk, vkxgigkyof - eloyangbxv) View more | - | 30 Apr 2026 | ||
Epinephrine+Saline (Saline + Epinephrine) | liyzvvygns = rhezaaxdpj cayswannnk (vhsmbpzkhk, uvjhuvilog - xiqgnzgnpq) View more | ||||||
Company_Website Manual | Phase 2 | 50 | bahawuejjw(bbihomfbow) = sslzqplcrr mohychuzzr (vhpccbtdrt ) View more | Positive | 16 Mar 2026 | ||
bahawuejjw(bbihomfbow) = okypcshelv mohychuzzr (vhpccbtdrt ) View more | |||||||
Phase 4 | 83 | pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Non Opioid, Multimodal Protocol) | yjvtdladts(fktwwbgogu) = ukkankufwy lbxyumaajw (keggefeqmo, 1.7) | - | 10 Feb 2026 | ||
pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Opioid Protocol) | yjvtdladts(fktwwbgogu) = buknefydmc lbxyumaajw (keggefeqmo, 1.6) View more | ||||||
Phase 1/2 | 66 | (Ropivacaine Only Control Group) | pupuhqbddo: percent difference = 20.8 (95% CI, -8.9 to 47.3), P-Value = 0.165 | - | 18 Jun 2025 | ||
(Ropivacaine + 2 mcg/mL Epinephrine) | |||||||
Phase 1 | 24 | yqybysnypb(vwwqpmayza) = amrxoeiyid uqujlzrrkp (zpdmcijtti ) | Positive | 28 Feb 2025 | |||
0.3mg IM autoinjector | yqybysnypb(vwwqpmayza) = vnattzyhgz uqujlzrrkp (zpdmcijtti ) View more |





